Colistin is a rapidly acting bactericidal antimicrobial agent that possesses a post antibiotic effect against MDRO Gram-negative bacteria, such as as Pseudomonas aeruginosa, Acinetobacterbaumannii, and Klebsiella pneumonia.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
330
High Dose Colistin
Standard Dose Colistin
King Saud Medical City
Riyadh, Riyadh Region, Saudi Arabia
RECRUITINGEvaluate safety of high dose Colistin
Evaluate the safety of high dose Colistin to treat MDRO infection in critically ill patients. The safety of high dose Colistin will be determined by number of participants whom renal function will be deviated from the baseline after administering high dose of Colistin.
Time frame: 7 to 21 days after giving Colistin
All cause mortality
Time frame: 7 days after the end of therapy or at 28 days after enrollment
Ventilation free days
Time frame: 28 days after enrollment
Length of ICU stay
Time frame: 28 days after enrollment
Microbiological response
whole body cultures will be done at day 7 of treatment and at the end of therapy
Time frame: A day 7 and at the end of therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.